Use of the piggy bac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral Vectors

Human Gene Therapy Methods

Volumn 25, Issue 4, 2014, Pages 253-260

  Feldman, Steven A ^a   Xu, Hui ^a   Black, Mary A ^a   Park, Tristen S ^a   Robbins, Paul F ^a   Kochenderfer, James N ^a   Morgan, Richard A ^b   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BLUEBIRD BIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETROVIRUS VECTOR; SELF INACTIVATING GAMMA RETROVIRUS VECTOR; UNCLASSIFIED DRUG; CYTOKINE; GREEN FLUORESCENT PROTEIN; TRANSPOSON;

ARTICLE; CELL CLONE; HUMAN; HUMAN CELL; NONHUMAN; PACKAGING; PIGGYBAC TRANSPOSON; PRIORITY JOURNAL; SUPERNATANT; TRANSPOSON; ANIMAL; CELL LINE; CYTOLOGY; FLOW CYTOMETRY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; METABOLISM; MONONUCLEAR CELL; MOUSE; PROCEDURES; RETROVIRUS;

ANIMALS; CELL LINE; CYTOKINES; DNA TRANSPOSABLE ELEMENTS; FLOW CYTOMETRY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; MICE; RETROVIRIDAE; TRANSFECTION;

EID: 84906691164     PISSN: 19466536     EISSN: 19466544     Source Type: Journal    
DOI: 10.1089/hgtb.2014.071     Document Type: Article

References (34)

1. Blaese, R.M., Culver, K.W., Miller, A.D., et al. (1995). T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270, 475-480.
2. Cary, L., Goebel, M., Corsaro, B., et al. (1989). Transposon mutagenesis of baculoviruses: analysis of Trichoplusia ni transposon IFP2 insertions within the FP-locus of nuclear polyhedrosis virus. Virology 172, 156-169.
3. Cavazzana-calvo, M., Jacein-bey, S., De Saint Basile, G., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672.
4. Coroadinha, A.S., Schucht, R., Gama-norton, L., et al. (2006). The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange. J. Biotechnol. 124, 457-468.
5. Feldman, S.A., Goff, S.L., Xu, H., et al. (2011). Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells. Hum. Gene Ther. 22, 107-115.
6. Fraser, M.J., Ciszczon, T., Elick, T., and Bauser, C. (1996). Precise excision of TTAA-specific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera. Insect Mol. Biol. 5, 141-151.
7. Gaspar, H.B., Parsley, K.L., Howe, S., et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-2187.
8. Geurts, A., Yang, Y., Clark, K., et al. (2003). Gene transfer into genomes of human cells by the Sleeping Beauty transposon system. Mol. Ther. 8, 108-117.
9. Hacein-bey-abina, S., Von kale, C., Schmidt, M., et al. (2003). A serious adverse event after successful gene therapy for Xlinked severe combined immunodeficiency. N. Engl. J. Med. 348, 255-256.
10. Heslop, H.E., Ng, C.Y.C., Li, C., et al. (1996). Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. 2, 551-555.
11. Hughes, M.S., Yu, Y.Y., Dudley, M.E., et al. (2005). Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions. Hum. Gene Ther. 16, 457-472.
12. Kochenderfer, J.N., Feldman, S.A., Zhao, Y., et al. (2009). Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689-702.
13. Kochenderfer, J.N., Wilson, W.H., Janik, J.E., et al. (2010). Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102.
14. Kochenderfer, J.N., Dudley, M.E., Maric, I., et al. (2011). Dramatic regression of chronic lymphocytic leukemia in the first patient treated with donor-derived genetically-engineered anti-CD19-chimeric-antigen-receptor- expressing T cells after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 17, S158.
15. Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., et al. (2012). B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720.
16. Loew, R., Meyer, Y., Kuehlcke, K., et al. (2009). A new PG13-based packaging cell line for stable production of clinicalgrade self-inactivating [gamma]-retroviral vectors using targeted integration. Gene Ther. 17, 272-280.
17. Maetzig, T., Galla, M., Baum, C., and Schambach, A. (2011). Gammaretroviral vectors: biology, technology and application. Viruses 3, 677-713.
18. Modlich, U., Bohne, J., Schmidt, M., et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108, 2545-2553.
19. Modlich, U., Navarro, S., Zychlinski, D., et al. (2009). Insertional transformation of hematopoietic cells by selfinactivating lentiviral and gammaretroviral vectors. Mol. Ther. 17, 1919-1928.
20. Montini, E., Cesana, D., Schmidt, M., et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotech. 24, 687-696.
21. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129.
22. Onodera, M., Yachie, A., Nelson, D.M., et al. (1997). A simple and reliable method for screening retroviral producer clones without selectable markers. Hum. Gene Ther. 8, 1189-1194.
23. Ott, M.G., Schmidt, M., Schwarzwaelder, K., et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
24. Robbins, P.F., Li, Y.F., El-Gamil, M., et al. (2008). Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J. Immunol. 180, 6116-6131.
25. Robbins, P.F., Morgan, R.A., Feldman, S.A., et al. (2011). Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924.
26. Schambach, A., Galla, M., Maetzig, T., et al. (2007). Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol. Ther. 15, 1167-1173.
27. Schucht, R., Coroadinha, A.S., Zanta-Boussif, M.A., et al. (2006). A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors. Mol. Ther. 14, 285-292.
28. Segura, M.M., Kamen, A.A., and Garnier, A. (2011). Overview of current scalable methods for purification of viral vectors. In Viral Vectors for Gene Therapy. O.-W. Merten and M. Al-Rubeai, eds. (Humana Press, New York, NY) pp. 89-116.
29. Singh, H., Figliola, M.J., Dawson, M.J., et al. (2013). Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS ONE 8, e64138.
30. Topalian, S., Solomon, D., and Rosenberg, S. (1989). Tumorspecific cytolysis by lymphocytes infiltrating human melanomas. J. Immunol. 142, 3714-3725.
31. Walter, E.A., Greenberg, P.D., Gilbert, M.J., et al. (1995). Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333, 1038-1044.
32. Wilson, M.H., Coates, C.J., and George, A.L. (2007). PiggyBac transposon-mediated gene transfer in human cells. Mol. Ther. 15, 139-145.
33. Wu, X., Li, Y., Crise, B., and Burgess, S.M. (2003). Transcription start regions in the human genome are favored targets for mlV integration. Science 300, 1749-1751.
34. Zychlinski, D., Schambach, A., Modlich, U., et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16, 718-725.